JP2001526224A5 - - Google Patents

Download PDF

Info

Publication number
JP2001526224A5
JP2001526224A5 JP2000525105A JP2000525105A JP2001526224A5 JP 2001526224 A5 JP2001526224 A5 JP 2001526224A5 JP 2000525105 A JP2000525105 A JP 2000525105A JP 2000525105 A JP2000525105 A JP 2000525105A JP 2001526224 A5 JP2001526224 A5 JP 2001526224A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
fpt inhibitor
substituted
proliferative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000525105A
Other languages
English (en)
Japanese (ja)
Other versions
JP4502503B2 (ja
JP2001526224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/026224 external-priority patent/WO1999032114A1/en
Publication of JP2001526224A publication Critical patent/JP2001526224A/ja
Publication of JP2001526224A5 publication Critical patent/JP2001526224A5/ja
Application granted granted Critical
Publication of JP4502503B2 publication Critical patent/JP4502503B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000525105A 1997-12-22 1998-12-21 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ Expired - Fee Related JP4502503B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
US09/181,969 1998-10-29
US09/143,529 1998-10-29
US08/996,027 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (3)

Publication Number Publication Date
JP2001526224A JP2001526224A (ja) 2001-12-18
JP2001526224A5 true JP2001526224A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4502503B2 JP4502503B2 (ja) 2010-07-14

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525105A Expired - Fee Related JP4502503B2 (ja) 1997-12-22 1998-12-21 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ

Country Status (25)

Country Link
EP (1) EP1041985B1 (cg-RX-API-DMAC7.html)
JP (1) JP4502503B2 (cg-RX-API-DMAC7.html)
KR (1) KR100700907B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129431C (cg-RX-API-DMAC7.html)
AR (1) AR017440A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317697T1 (cg-RX-API-DMAC7.html)
AU (1) AU756762B2 (cg-RX-API-DMAC7.html)
BR (1) BR9814419A (cg-RX-API-DMAC7.html)
CA (1) CA2315693C (cg-RX-API-DMAC7.html)
CL (1) CL2007001889A1 (cg-RX-API-DMAC7.html)
CO (1) CO5080764A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298511B6 (cg-RX-API-DMAC7.html)
DE (1) DE69833509T2 (cg-RX-API-DMAC7.html)
DK (1) DK1041985T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255196T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0102473A3 (cg-RX-API-DMAC7.html)
IL (1) IL136462A0 (cg-RX-API-DMAC7.html)
MY (1) MY137303A (cg-RX-API-DMAC7.html)
NO (1) NO326832B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504928A (cg-RX-API-DMAC7.html)
PE (1) PE20000042A1 (cg-RX-API-DMAC7.html)
PT (1) PT1041985E (cg-RX-API-DMAC7.html)
SK (1) SK285584B6 (cg-RX-API-DMAC7.html)
TW (1) TW581763B (cg-RX-API-DMAC7.html)
WO (1) WO1999032114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
WO1997036583A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
AU3215197A (en) * 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Similar Documents

Publication Publication Date Title
JP2003529540A5 (cg-RX-API-DMAC7.html)
CA2315693A1 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
AU2002248542B9 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP2227296B1 (en) Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CA2665539A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
RU2008117295A (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
US7008936B2 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
HRP20110245T1 (hr) Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze
MXPA05003119A (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
CA2497440A1 (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
RU2008122967A (ru) Имидазопиразины в качестве ингибиторов протеинкиназ
CA2497444A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
RU2002129000A (ru) Синергические способы и композиции для лечения рака
PA8444201A1 (es) Derivados ciclicos de sulfona
DE60113809D1 (de) Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
AU2002248542A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2499639A1 (en) Imidazopyridines as cyclin dependent kinase inhibitors
CA2497539A1 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2557184A1 (en) Pyrazolotriazines as kinase inhibitors
JP2004513885A5 (cg-RX-API-DMAC7.html)
CA2499593A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
CA2424797A1 (en) Methods of inducing cancer cell death and tumor regression
ATE236620T1 (de) Zusammensetzungen mit langsamer freigabe enthaltend eine zinkverbindung und vitamin c- derivate
RU2003108865A (ru) Трициклические противоопухолевые соединения, являющиеся ингибиторами фарнезилпротеинтрансферазы